Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel molecular targets for urothelial carcinoma.
Faltas BM, Karir BS, Tagawa ST, Rosenberg JE. Faltas BM, et al. Expert Opin Ther Targets. 2015 Apr;19(4):515-25. doi: 10.1517/14728222.2014.987662. Epub 2015 Jan 30. Expert Opin Ther Targets. 2015. PMID: 25633079 Free PMC article. Review.
Clonal evolution of chemotherapy-resistant urothelial carcinoma.
Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA. Faltas BM, et al. Nat Genet. 2016 Dec;48(12):1490-1499. doi: 10.1038/ng.3692. Epub 2016 Oct 17. Nat Genet. 2016. PMID: 27749842 Free PMC article.
Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.
Shohdy KS, Vlachostergios PJ, Abdel-Malek RR, Faltas BM. Shohdy KS, et al. Among authors: faltas bm. Expert Opin Ther Targets. 2019 Feb;23(2):83-86. doi: 10.1080/14728222.2019.1559828. Epub 2018 Dec 17. Expert Opin Ther Targets. 2019. PMID: 30558440 No abstract available.
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J, Tagawa ST, Nanus DM, Beltran H, Molina AM, Khani F, Miguel Mosquera J, Xylinas E, Shariat SF, Scherr DS, Rubin MA, Lerner SP, Matin SF, Elemento O, Faltas BM. Robinson BD, et al. Among authors: faltas bm. Nat Commun. 2019 Jul 5;10(1):2977. doi: 10.1038/s41467-019-10873-y. Nat Commun. 2019. PMID: 31278255 Free PMC article.
Common germline-somatic variant interactions in advanced urothelial cancer.
Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H, Sternberg CN, Motanagh S, Robinson BD, Xiang J, Fan X, Chung WK, Rubin MA, Elemento O, Sboner A, Mosquera JM, Faltas BM. Vosoughi A, et al. Among authors: faltas bm. Nat Commun. 2020 Dec 3;11(1):6195. doi: 10.1038/s41467-020-19971-8. Nat Commun. 2020. PMID: 33273457 Free PMC article.
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, Tagawa ST, Molina AM, Sternberg CN, Nanus DM, Mosquera JM, Elemento O, Sonpavde GP, Grivas P, Vogelzang NJ, Faltas BM. Shohdy KS, et al. Among authors: faltas bm. Br J Cancer. 2022 Feb;126(3):430-439. doi: 10.1038/s41416-021-01648-8. Epub 2022 Jan 19. Br J Cancer. 2022. PMID: 35046520 Free PMC article.
97 results